Education
About Us
Working with TipRanks
Follow Us
Conduit Pharmaceuticals (CDT)
NASDAQ:CDT
CDT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.70 - $622.50
Previous Close$0.08
Volume254.55M
Average Volume (3M)351.47K
Market Cap
$4.28M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.49
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-21.28
Shares Outstanding2,405,140
10 Day Avg. Volume125,016
30 Day Avg. Volume351,466
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Conduit Pharmaceuticals News
CDT FAQ
What was Conduit Pharmaceuticals’s price range in the past 12 months?
Conduit Pharmaceuticals lowest stock price was $1.70 and its highest was $622.50 in the past 12 months.
What is Conduit Pharmaceuticals’s market cap?
Conduit Pharmaceuticals’s market cap is $4.28M.
When is Conduit Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Conduit Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Conduit Pharmaceuticals overvalued?
According to Wall Street analysts Conduit Pharmaceuticals’s price is currently Overvalued.
Does Conduit Pharmaceuticals pay dividends?
Conduit Pharmaceuticals does not currently pay dividends.
What is Conduit Pharmaceuticals’s EPS estimate?
Conduit Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Conduit Pharmaceuticals have?
Conduit Pharmaceuticals has 2,405,140 shares outstanding.
What happened to Conduit Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Conduit Pharmaceuticals?
Currently, no hedge funds are holding shares in CDT
Conduit Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 1.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-99.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
48.89%
Trailing 12-Months
Company Description
Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Conduit Pharmaceuticals (CDT) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Matinas BioPharma
―
Quoin Pharmaceuticals
―
Silo Pharma
―
CNS Pharmaceuticals
―
Galecto
―
Ownership Overview
58.94% Insiders
0.07% Mutual Funds
0.07% Other Institutional Investors
40.95% Public Companies and Individual Investors
Options Prices
Currently, No data available
---